Trial Profile

Randomized phase III study of gemcitabine plus S-1 combination therapy versus gemcitabine plus cisplatin combination therapy in advanced biliary tract cancer (JCOG1113, FUGA-BT)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 23 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gimeracil/oteracil/tegafur (Primary) ; Cisplatin; Gemcitabine
Indications Adenocarcinoma; Adenosquamous carcinoma; Biliary cancer; Carcinoma; Cholangiocarcinoma; Gallbladder cancer; Squamous cell cancer
Focus Therapeutic Use
Acronyms FUGA-BT

05 Jun 2025 Results of a subgroup analysis of ICC patients , published in the Japanese Journal of Clinical Oncology
21 Jan 2023 Results of exploratory analysis of JCOG1113 (n=352) assessing to compare clinical features among the primary sites gemcitabine-based chemotherapy in patients with biliary tract cancer, presented at the 2023 Gastrointestinal Cancers Symposium.
22 Jan 2022 Results presented at the 2022 Gastrointestinal Cancers Symposium

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com